phospholipid Inhibitors
2 drugsAbout phospholipid
Phospholipids are essential cell membrane components with hydrophilic heads and hydrophobic tails. They play crucial roles in cellular structure, signaling, and metabolism.
Phospholipids are emerging as therapeutic targets, though direct genetic evidence linking them to specific diseases is currently unavailable. Drugs targeting phospholipids are already in clinical use, suggesting their potential as druggable targets.
Two FDA-approved drugs, PENTAM and PENTAMIDINE ISETHIONATE, target phospholipids as small molecules. These drugs, marketed by Fresenius Kabi and SETON PHARMS, are used in other therapeutic areas.
Top phospholipid Drugs
Fresenius Kabi and SETON PHARMS are the only companies with approved phospholipid-targeting drugs.
Low market concentration suggests an opportunity for new entrants in this space.
phospholipid Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets phospholipid, using small molecule modality.
Exploring alternative modalities like antibodies or peptides could create differentiation.
phospholipid Clinical Trials 9 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on phospholipid. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 4 | 3 | 1 | 0 | 75% |
| Phase 2 | 2 | 1 | 1 | 0 | 50% |
| Phase 3 | 2 | 1 | 0 | 1 | 100% |
| Phase 4 | 1 | 0 | 0 | 1 | - |
Top Sponsors
By Modality
Top Conditions
Top Drugs
phospholipid Drug Approval Timeline (1984 - 1984)
The first drug was approved in 1984 (PENTAM), and the most recent in 1992 (PENTAMIDINE ISETHIONATE).
The long gap since the last approval suggests potential for innovation in this area.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 2 companies competing
- • Market share by company
Full Drug Portfolio
- • All 2 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 2-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 7 (1 company)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on phospholipid. A trial counts if an approved drug acting on phospholipid is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.